leadf
logo-loader
viewBiocept Inc

Biocept says published clinical data further validates Target Selector to identify cancer-related mutations

Data from the study, which examined 127 clinical assays, were published in the peer-reviewed Journal of Clinical Pathology

Biocept Inc - Biocept Inc says newly published clinical data further validates its Target Selector technology to identify cancer-related mutations in liquid biopsy samples
The technology collects and analyzes molecular markers linked to tumors in circulating tumor cells as well as plasma

Biocept Inc (NASDAQ:BIOC) announced Monday that newly published clinical data further validates the company's Target Selector technology to identify cancer-related mutations in liquid biopsy samples. 

The data were published in the peer-reviewed Journal of Clinical Pathology which highlighted Biocept’s flagship Target Selector qPCR Assay using "Switch Blocker" technology that collects and analyzes molecular markers linked to tumors in circulating tumor cells, as well as plasma.

“Results from this study showed a very high concordance rate between our liquid biopsy testing and tissue biopsy, providing further clinical validation of our Target Selector technology," said Dr Veena Singh, senior vice president and senior medical director, in a statement. 

READ: Biocept prices $6.6M registered direct offering priced at-the-market

"Our clinical testing demonstrates best-in-class detection of alterations down to a single mutant copy, not only in an analytical setting but in a clinical setting as well. Further, the ability to inform clinical decision making in a significantly more cost-effective manner potentially affords the healthcare system a highly sensitive and cost-effective option," Singh added. 

The San Diego-based company said the study examined 127 clinical assays for mutations commonly associated with cancer found in the EGFR, BRAF and KRAS genes. Each Target Selector assay in the study demonstrated extremely high accuracy, sensitivity and specificity when compared to results obtained from tissue samples, showing a 93%-96% concordance to blinded tissue samples across all assays.

"The continued validation of our technology demonstrates its ability to non-invasively identify biomarkers specific to cancer, and to aid physicians in selecting optimal therapeutic treatments for their patients," said CEO Michael Nall.

"We are pleased to report that our biomarker testing has been performed in more than 25,000 patients to date, and results from this study further illustrate the enhanced performance of our Target Selector technology."

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 4.86 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $65.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read